CA3177415A1 - Methods of treating acute respiratory distress syndrome with activators of tie-2 - Google Patents
Methods of treating acute respiratory distress syndrome with activators of tie-2 Download PDFInfo
- Publication number
- CA3177415A1 CA3177415A1 CA3177415A CA3177415A CA3177415A1 CA 3177415 A1 CA3177415 A1 CA 3177415A1 CA 3177415 A CA3177415 A CA 3177415A CA 3177415 A CA3177415 A CA 3177415A CA 3177415 A1 CA3177415 A1 CA 3177415A1
- Authority
- CA
- Canada
- Prior art keywords
- administration
- subject
- substituted
- group
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063028317P | 2020-05-21 | 2020-05-21 | |
| US63/028,317 | 2020-05-21 | ||
| PCT/US2021/033495 WO2021236985A1 (en) | 2020-05-21 | 2021-05-20 | Methods of treating acute respiratory distress syndrome with activators of tie-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3177415A1 true CA3177415A1 (en) | 2021-11-25 |
Family
ID=78707586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3177415A Pending CA3177415A1 (en) | 2020-05-21 | 2021-05-20 | Methods of treating acute respiratory distress syndrome with activators of tie-2 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12544362B2 (https=) |
| EP (1) | EP4153237A4 (https=) |
| JP (1) | JP7783834B2 (https=) |
| CN (1) | CN115666651A (https=) |
| AU (1) | AU2021275224A1 (https=) |
| CA (1) | CA3177415A1 (https=) |
| WO (1) | WO2021236985A1 (https=) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2195958C1 (ru) | 2002-02-19 | 2003-01-10 | Центральный научно-исследовательский институт туберкулеза РАМН | Способ лечения синдрома острого повреждения легких после расширенных оперативных вмешательств |
| WO2004075838A2 (en) * | 2003-02-21 | 2004-09-10 | Rikshospitalet-Radiumhospitalet Hf | Method and compositions for the treatment of meconium aspiration syndrome |
| WO2005034929A2 (en) | 2003-10-10 | 2005-04-21 | Fibrogen, Inc. | Tissue remodeling and vascularization |
| WO2007084136A2 (en) | 2006-01-23 | 2007-07-26 | Ony, Inc. | Treatment of acute respiratory distress syndrome |
| DK2385763T3 (en) * | 2009-01-12 | 2018-07-16 | Aerpio Therapeutics Inc | METHODS OF TREATING VASCULAR LEAK SYNDROME |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| CA2909080C (en) * | 2013-04-11 | 2022-07-26 | Sunnybrook Research Institute | Methods, uses and compositions of tie2 agonists |
| US9381212B2 (en) * | 2014-01-10 | 2016-07-05 | Mallinckrodt Hospital Products IP Limited | Methods of using inhaled nitric oxide gas for treatment of acute respiratory distress syndrome in children |
| WO2017100796A1 (en) * | 2015-12-11 | 2017-06-15 | SINACA, Academia | Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers |
| CA3137138A1 (en) * | 2019-04-18 | 2020-10-22 | EyePoint Pharmaceuticals, Inc. | Methods of treating hypertension with activators of tie-2 |
-
2021
- 2021-05-20 CN CN202180035947.4A patent/CN115666651A/zh active Pending
- 2021-05-20 US US17/999,145 patent/US12544362B2/en active Active
- 2021-05-20 CA CA3177415A patent/CA3177415A1/en active Pending
- 2021-05-20 AU AU2021275224A patent/AU2021275224A1/en active Pending
- 2021-05-20 JP JP2022569498A patent/JP7783834B2/ja active Active
- 2021-05-20 WO PCT/US2021/033495 patent/WO2021236985A1/en not_active Ceased
- 2021-05-20 EP EP21809512.3A patent/EP4153237A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4153237A1 (en) | 2023-03-29 |
| WO2021236985A1 (en) | 2021-11-25 |
| JP7783834B2 (ja) | 2025-12-10 |
| EP4153237A4 (en) | 2024-07-03 |
| US20240299367A1 (en) | 2024-09-12 |
| CN115666651A (zh) | 2023-01-31 |
| AU2021275224A1 (en) | 2022-10-13 |
| JP2023526790A (ja) | 2023-06-23 |
| US12544362B2 (en) | 2026-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020196750A (ja) | 線維症を処置するためのセニクリビロック併用療法 | |
| KR102689822B1 (ko) | 코로나바이러스의 치료 방법 | |
| US20230129866A1 (en) | Methods of treating respiratory disease with deupirfenidone | |
| JP2019531346A (ja) | 甲状腺関連副作用を低下させる方法 | |
| TW202003503A (zh) | 治療纖維化疾病之方法 | |
| US20190262321A1 (en) | Methods of treating diabetic nephropathy using hptpb inhibitors | |
| US20200352914A1 (en) | Methods of treating hypertension with activators of tie-2 | |
| JP2017507949A (ja) | マトリックスメタロプロテイナーゼ９に対する抗体およびその使用の方法 | |
| US12544362B2 (en) | Methods of treating acute respiratory distress syndrome with activators of Tie-2 | |
| WO2019157337A1 (en) | Formulations of kinase inhibitors and prostanoids | |
| US20230125415A1 (en) | Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia | |
| US20230151093A1 (en) | Methods of treating immune mediated pulmonary injury | |
| US20250025450A1 (en) | Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone | |
| EP4134078A1 (en) | Injectable melatonin composition for the treatment of viral diseases | |
| US20230357418A1 (en) | Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia | |
| US20230265081A1 (en) | Methods of treating coronavirus | |
| CN111888355A (zh) | 盐酸阿比朵尔在制备用于治疗脓毒症疾病的药物中的应用 | |
| JP2017514849A (ja) | 特発性肺線維症の治療方法 | |
| EP4153310B1 (en) | Bbeta-15-42 for the treatment of viral endothelitis | |
| US20250205268A1 (en) | Treatment of viruses with antiviral nucleosides | |
| US20240025991A1 (en) | Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist | |
| WO2023084489A1 (en) | Methods of treating coronavirus disease 2019 | |
| CN115397404A (zh) | 用于治疗covid-19的cxcl8抑制剂 | |
| JPWO2005056009A1 (ja) | 肺疾患治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250505 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250505 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250505 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250506 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250516 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250516 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250721 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250721 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250721 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250721 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250725 |